EMAIL THIS PAGE TO A FRIEND

Cancer letters

NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.


PMID 26188279

Abstract

Glioblastoma multiforme (GBM) is the most frequent and most aggressive brain tumor in adults. The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas. However, a considerable number of GBM cases are refractory to TMZ, the need for more effective therapeutic options is overwhelming. Mounting evidence shows that endogenous AKT (protein kinase B) activity can be activated in response to clinically relevant concentrations of TMZ. AKT activation correlated with the increased tumorigenicity, invasiveness and stemness and overexpression of an active form of AKT increases glioma cell resistance to TMZ. Previous studies also show that TMZ contributes to glioma cell apoptosis by inhibiting mTOR signaling. Thus, we hypothesized that the dual PI3K-mTOR inhibitor NVP-BEZ235 may act as antitumor agent against gliomas and potentiate the cytotoxicity of TMZ. In the present study, we found that NVP-BEZ235 treatment of glioma cell lines led to G1 cell cycle arrest, and induced apoptosis. Combination treatment with both TMZ and NVP-BEZ235 resulted in synergistically inhibited glioma cell growth and induced apoptosis (combination index CI<1) in a subset of glioma cell lines, as shown in the increased levels of Bax, and active Caspase-3, and decreased level of Bcl-2. Furthermore, NVP-BEZ235 treatment reversed p-AKT levels enhanced by TMZ. Inhibition of mTOR (p70S6K) signaling with the combination of TMZ and NVP-BEZ235 can be augmented beyond that achieved using each agent individually. In vivo xenograft models in mice, the combinatorial treatment with TMZ and NVP-BEZ235 significantly reduced tumor growth rates and prolonged median survival of tumor-bearing mice. These findings exhibit that TMZ in combination with NVP-BEZ235 act synergistically to inhibit proliferation of glioma cells by down-regulating of the PI3K-AKT-mTOR pathway, suggesting TMZ and NVP-BEZ235 combination therapy may be an option for GBM treatment.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB3500343
Anti-Bax antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
HPA027878
Anti-BAX antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4502549
Anti-BAX antibody produced in rabbit, affinity isolated antibody
B8554
Anti-Bax antibody, Mouse monoclonal, clone 2D2, purified from hybridoma cell culture
SAB4502546
Anti-BAX, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4502547
Anti-BAX, C-Terminal antibody produced in rabbit, affinity isolated antibody
AV30161
Anti-CCNB1 antibody produced in rabbit, affinity isolated antibody
SAB2100360
Anti-CCNB1 antibody produced in rabbit, affinity isolated antibody
SAB2100362
Anti-CCND1 (ab1) antibody produced in rabbit, affinity isolated antibody
SAB2100363
Anti-CCND1 (ab2) antibody produced in rabbit, affinity isolated antibody
SAB2100364
Anti-CCND1 (ab3) antibody produced in rabbit, affinity isolated antibody
SAB1405510
Anti-CCND1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB2106484
Anti-CCND1 antibody produced in rabbit, affinity isolated antibody
C8831
Anti-Cyclin B1 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB4503501
Anti-Cyclin B1 antibody produced in rabbit, affinity isolated antibody
SAB4503502
Anti-Cyclin B1 antibody produced in rabbit, affinity isolated antibody
C5588 Anti-Cyclin D1 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB2101602
Anti-NKX3-1 (ab1) antibody produced in rabbit, affinity isolated antibody
SAB2101603
Anti-NKX3-1 (ab2) antibody produced in rabbit, affinity isolated antibody
SAB1412056
ANTI-NKX3-1 antibody produced in mouse, clone 3C1, purified immunoglobulin, buffered aqueous solution
SAB4503847
Anti-phospho-4E-BP1 (pSer64) antibody produced in rabbit, affinity isolated antibody
SAB4504328
Anti-phospho-4E-BP1 (pThr36) antibody produced in rabbit, affinity isolated antibody
SAB4504329
Anti-phospho-4E-BP1 (pThr45) antibody produced in rabbit, affinity isolated antibody
SAB4503848
Anti-phospho-4E-BP1 (pThr69) antibody produced in rabbit, affinity isolated antibody
SAB4504686
Anti-phospho-4E-BP1 (pThr70) antibody produced in rabbit, affinity isolated antibody
SAB4300179
Anti-phospho-EIF4EBP1 (pThr45) antibody produced in rabbit, affinity isolated antibody
B9054 Monoclonal Anti-Bax antibody produced in mouse, 2 mg/mL, clone 5B7, purified immunoglobulin, buffered aqueous solution
WH0000581M1
Monoclonal Anti-BAX antibody produced in mouse, clone 1F5-1B7, purified immunoglobulin, buffered aqueous solution
WH0000891M1
Monoclonal Anti-CCNB1 antibody produced in mouse, clone 1C8, purified immunoglobulin, buffered aqueous solution
SAB5300329 Monoclonal Anti-CCNB1 antibody produced in mouse, clone 1B10, ascites fluid